Company Profile for NPS Pharmaceuticals

--(BUSINESS WIRE)--NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently conducting two Phase 3 registration studies. Teduglutide, a proprietary analog of GLP-2 is being evaluated as GATTEX(TM) in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and in preclinical development for gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Kirin, Nycomed, and Ortho-McNeil. Additional information is available at http://www.npsp.com.

Company:	NPS Pharmaceuticals
Headquarters Address:	550 Hills Drive
	Third Floor
	Bedminster, NJ 07921
Main Telephone:	908-450-5300
Website:	www.npsp.com
Ticker/ISIN:	NPSP(NASDAQ)/US62936P1030
Type of Organization:	Public
	PR
Industry:	Biotechnology
Key Executives:	CEO: Francois Nader
	CFO: Luke Beshar
	CMO: Roger Garceau
Investor Relations
Contact:	Susan Mesco
Phone:	908-450-5300
Email:	[e-mail]
Investor Relations
Contact:	Gail Brophy
Phone:	908-450-5300
Email:	[e-mail]